



6 November 2023

ASX Compliance Pty Ltd  
20 Bridge Street  
Sydney NSW 2000

By email: [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

**Bod Science Limited (ASX: BOD)  
Request for extension of Voluntary Suspension**

Bod Science Limited ACN 601 225 441 (the **Company** or **Bod**) refers to the suspension from quotation under Listing Rule 17.5 which commenced on 1 November 2023 and the voluntary suspension which commenced on 2 November 2023.

In the request for voluntary suspension dated 2 November 2023, Bod requested that the voluntary suspension remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Monday, 6 November 2023.

Bod wishes to remain in voluntary suspension until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Wednesday, 8 November 2023. The two trading day extension to the voluntary suspension is required in order to finalise the Company's proposed capital raising.

In accordance with Listing Rule 17.2, the Company advises that:

1. The extension to the voluntary suspension is required to enable the Company to finalise its capital raising in an orderly manner.
2. The Company expects the voluntary suspension to last for an additional two trading days (being a total of five trading days of suspension).
3. The Company requests that the voluntary suspension remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Wednesday, 8 November 2023.
4. The Company is not aware of any reason why its securities should not be suspended, or of any other information available at this stage that is relevant to the voluntary suspension.

**Authorised for release by the Chair of Bod Science Limited.**

**ENDS**

**About Bod Science**

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers. The Company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
Info@bodaustralia.com  
+61 2 9199 5018

Amalie Schreurs  
White Noise Communications  
amalie@whitenoisecomms.com  
+61 431 636 033